Efficacy of Persian medicine herbal formulations (capsules and decoction) compared to standard care in patients with COVID-19, a multicenter open-labeled, randomized, controlled clinical trialRandomized Controlled Trial Published on 2021-11-012022-10-05 Journal: Phytotherapy research : PTR [Category] SARS, 임상, [키워드] accelerated anorexia chills clinical experience Clinical improvement conducted Controlled clinical trial coronavirus cough COVID-19 demonstrated dry cough Dyspnea Effect Endpoint fatigue FIVE headache herbal medicine hospital Hospital stay Hospitalized Iran microbial infection multicenter Multicenter trial Open-label Pain pandemic Patient patients patients with COVID-19 Persian medicine phytotherapy questionnaire Randomized respiratory diseases Result routine care secondary outcome Significant significantly sputum standard care Symptom symptoms of COVID-19 Tehran Tolerability Treatment treatment group vertigo [DOI] 10.1002/ptr.7277 PMC 바로가기 [Article Type] Randomized Controlled Trial
Differentiated service delivery models among PLHIV in Akwa Ibom and Cross River States, Nigeria during the COVID‐19 pandemic: descriptive analysis of programmatic dataCOVID-19 대유행 기간 동안 Akwa Ibom 및 Cross River States, Nigeria의 PLHIV 간의 차별화된 서비스 제공 모델: 프로그램 데이터에 대한 기술 분석Supplement: Research Article Published on 2021-10-282022-09-10 Journal: Journal of the International AIDS Society [Category] MERS, SARS, 치료제, [키워드] Adults Analysis Antiretroviral therapy ARC ART Bivariate analyses Characteristics children clinical outcomes clinics club Community conducted continuity COVID‐19 COVID‐19 Critical Descriptive analysis difference differentiated service delivery enrolled exceeded FIVE group improve clinical outcomes Kaplan–Meier mechanism Nigeria offered P ‐value Patient people living with HIV PLHIV proportion proportions rapid increase receive receiving Result retention retrospective cohort study river Sex difference significantly higher standard care suppressed Travel Treatment treatment retention Viral Viral suppression with HIV [DOI] 10.1002/jia2.25820 PMC 바로가기 [Article Type] Supplement: Research Article
Beneficial effects of a mouthwash containing an antiviral phthalocyanine derivative on the length of hospital stay for COVID-19: randomised trialCovid-19의 입원 기간에 대한 항 바이러스 프탈로시아닌 유도체를 함유하는 구강 세척의 유익한 효과 : 무작위 시험Randomized Controlled Trial Published on 2021-10-072022-08-13 Journal: Scientific Reports [Category] MERS, SARS, 임상, 치료기술, 치료제, [키워드] adjuvant Admission age anionic phthalocyanine derivative Antiviral antiviral activity Antiviral effect antiviral effects APD association both groups Care clinical clinical condition clinical study clinical trial Comorbidities Compound conducted Contamination control group COVID-19 cytotoxicity death demonstrated dissemination duration of symptom Effect effective evaluated experimental group group Health Organization hospital hospital discharge Hospital stay hospitalized patient ICU ICU care in both group in vitro indicated infected with SARS-CoV-2 Infection intensive care unit Intervention LOS Mouthwash mouthwash protocol nasal nonactive mouthwash number of comorbidities Patient pharyngeal photoexcitation phthalocyanine positive presence of comorbidities protocol Randomised trial Randomized controlled trial reduce reduced reducing reduction Registered Research risk SARS-CoV-2 SARS-CoV-2 viral load severity of symptom Sex significantly Spread standard care Symptom tested the median the patient Treatment Trial registration triple-blind triple-blind randomized controlled trial Two-arm Viral World Health Organization [DOI] 10.1038/s41598-021-99013-5 PMC 바로가기 [Article Type] Randomized Controlled Trial
Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trialsCOVID-19에 대한 Janus kinase inhibitors의 임상적 효능 및 안전성: 무작위 대조 시험의 체계적인 검토 및 메타 분석Meta-Analysis Published on 2021-10-012022-09-11 Journal: International immunopharmacology [Category] SARS, 신약개발, 임상, [키워드] 95% CI adverse event all-cause mortality rate And tofacitinib Baricitinib clinical Clinical efficacy Clinical outcome clinical recovery ClinicalTrials Control Controlled controlled trials controls COVID-19 COVID-19 patients Efficacy and safety hospitalized COVID-19 patients inception inhibitor Invasive mechanical ventilation Jak JAK inhibitor jak inhibitors janus Janus kinase Janus kinase inhibitor Kinase inhibitor Meta-analysis mortality rate no significant difference Placebo Primary outcome Randomized controlled trial Randomized controlled trials RCT RCTs receiving risk ruxolitinib Safe searched Serious Adverse Event Serious Adverse Events standard care systematic review the patient Time to recovery Tofacitinib treating COVID-19 patient Treatment [DOI] 10.1016/j.intimp.2021.108027 PMC 바로가기 [Article Type] Meta-Analysis
Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled studyCOVID-19 치료에서 이버멕틴의 효능을 평가하는 임상 연구: 무작위 대조 연구Randomized Controlled Trial Published on 2021-10-012022-09-11 Journal: Journal of medical virology [Category] SARS, 임상, 치료제, [키워드] Chloroquine clinical control group coronavirus disease Coronavirus disease 2019 COVID-19 death rate Efficacy Endpoint evaluate group Hospital stay Hospitalized individual infected patients Ivermectin ivermectin dose ivermectin group mechanical ventilation Mild mild to moderate Moderate COVID-19 Mortality no statistically significant difference once daily Open-label outcome Patient patients with COVID-19 Prevent protocol Randomized randomized controlled study receive reducing required significant difference standard care Standard of care statistically significant statistically significant difference treat Treatment two group two groups [DOI] 10.1002/jmv.27122 PMC 바로가기 [Article Type] Randomized Controlled Trial
Effects of Shuanghuanglian oral liquids on patients with COVID-19: a randomized, open-label, parallel-controlled, multicenter clinical trialCOVID-19 환자에 대한 Shuanghuanglian 경구 액체의 효과: 무작위, 공개, 병행 대조, 다기관 임상 시험Randomized Controlled Trial Published on 2021-10-012022-09-11 Journal: Frontiers of medicine [Category] SARS, 유전자 메커니즘, 임상, [키워드] 95% CI Absorption addition baseline Chest computed tomography Chinese clinical trial Combination composed Computed tomography conducted control group COVID-19 disease dose Effect effective evaluated groups High dose High-dose Inflammatory low dose mean difference multicenter Multicenter trial Negative conversion nucleic acid occurred Open-label Patent Medicine Patient Pneumonia promoted Randomized reduction Safe SARS-CoV-2 Serious Adverse Event Serious Adverse Events Shuanghuanglian oral liquid significantly significantly higher standard care Standard therapy Swab test the patient Treatment [DOI] 10.1007/s11684-021-0853-6 PMC 바로가기 [Article Type] Randomized Controlled Trial
Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial경증에서 중등도의 CovID-19 (Atomic2) 환자의 아지트로 마이신 대 표준 치료 : 개방형, 무작위 시험Randomized Controlled Trial Published on 2021-10-012022-08-13 Journal: The Lancet. Respiratory Medicine [Category] MERS, SARS, 임상, [키워드] 1:1 adjusted age Anti-inflammatory Antibacterial antiviral properties antiviral property assigned Azithromycin clinically Confirmed COVID-19 infection Consent COVID-19 COVID-19 infection death diagnosed did not reduce died effective enrolled finding funding hospital Hospital admission initial intention-to-treat principle management Mild-to-moderate mild-to-moderate disease once daily Open-label outcome Oxford participant Patient Pfizer presenting Primary outcome randomisation randomised Randomised trial Randomly recruitment reducing Registered removal reported risk Serious Adverse Event Serious Adverse Events standard care standard care group subsequent Support Symptoms therapeutic potential Treatment Trial University of Oxford was done were assessed [DOI] 10.1016/S2213-2600(21)00263-0 PMC 바로가기 [Article Type] Randomized Controlled Trial
Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients – a hypothetical studyResearch Article Published on 2021-09-182022-10-28 Journal: BMC health services research [Category] COVID-19, SARS, [키워드] Analysis Care clinical trials Cohort Cost effectiveness Cost Utility COVID-19 Decision tree Dexamethasone disease drug effective evaluated Health hospitalised COVID-19 patient Hospitalization hospitalized patient hospitalized patients hypothetical literature review morbidity and mortality Mortality novel corona virus objective parameter patient hospitalization Perspective pharmacoeconomics positive Remdesivir Result retrieved SARS-CoV-2 sensitivity analysis shown standard care Standard of care tested thresholds Treatment utility [DOI] 10.1186/s12913-021-06998-w PMC 바로가기 [Article Type] Research Article
Prophylactic potential of honey and Nigella sativa L. against hospital and community-based SARS-CoV-2 spread: a structured summary of a study protocol for a randomised controlled trial병원 및 지역사회 기반 SARS-CoV-2 확산에 대한 꿀과 Nigella sativa L.의 예방 가능성: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2021-09-152022-09-10 Journal: Trials [Category] SARS, 임상, [키워드] 1:1 adaptive allergy analyst approved asymptomatic patient blinded Blinding body weight Botany Care care providers chronic infection clinic clinical Clinical management clinical study clinical trial college Community conflict conflict of interest control group coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 case COVID-19-related symptom COVID-19-related symptoms death defined dextrose dissemination doctor Efficacy element Endpoint enrolled evaluate excluded exposure to Final futility high risk Honey hospital hospitalizations incidence include institutional review board Intention interim analysis investigator management guidelines masking moderate National Health Service Nigella Nigella Sativa number objective outcome Pakistan parallel group participant Participants Patient patients per day Placebo placebo group placebo-controlled Primary outcome principal investigator Prophetic Medicine Prophylactic protocol randomisation randomised randomised controlled trial randomization Randomized receive recruited recruitment Registered reported responsible risk Sample size SARS-CoV-2 screened secondary Secondary endpoints severity Site Standard standard care Standardization status Stratification Study protocol supplementary material the patient therapeutic potential therapy Trial university Version water website [DOI] 10.1186/s13063-021-05510-3 PMC 바로가기 [Article Type] Letter
Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled TrialCOVID-19 치료에서 렘데시비르의 효능: 무작위 대조 시험Randomized Controlled Trial Published on 2021-09-102022-09-11 Journal: The American Journal of Tropical Medicine and Hygi [Category] SARS, 임상, 치료제, [키워드] 1:1 addition Analysis antiviral therapy assigned benefit C-reactive protein clinical effectiveness comparable control group Controlled country COVID-19 D-dimer Dexamethasone effective Efficacy eight elevated Final final analysis followed by had no Hospital stay Hospitalized infused intravenously mechanical ventilation median Mortality mortality rate Older age Patient patients with COVID-19 positive Primary outcome Primary outcomes Randomly receive Remdesivir secondary outcome shown significantly significantly lower standard care the patient two group two groups [DOI] 10.4269/ajtmh.21-0606 PMC 바로가기 [Article Type] Randomized Controlled Trial